RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Personalized vaccine takes on head and neck cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS ≥ 1) will receive b…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Promising combo tackles tough head and neck cancers
Disease control Recruiting nowThis early-stage trial tests whether adding immunotherapy (pembrolizumab) and radiation before and during surgery can better treat head and neck cancers that persist or come back. About 45 adults with resectable tumors will participate. The main goal is to check safety and side e…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New drug plus precision radiation aims to tame recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a drug called camonsertib combined with precise radiation for head and neck cancer that has returned or cannot be surgically removed. The study aims to find the safest dose and see if the combination can control tumor growth. About 39 adults with cert…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Immunotherapy drug may beat standard chemo for recurrent head and neck cancer
Disease control Recruiting nowThis study compares the immunotherapy drug pembrolizumab to the usual chemotherapy plus radiation after surgery for head and neck cancer that has returned or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (like cancer at the surgical edge or spread to…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:10 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:57 UTC